Open AccessROS-1 re-arrangements and c-MET amplifications in adenocarcinoma lung: A tertiary care center study from North India
Author(s) -
Saumya Shukla,
Rahul Pandey,
Surya Kant,
Rajiv Garg,
Nuzhat Husain
Publication year - 2019
Publication title -
indian journal of pathology and microbiology/indian journal of pathology and microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.217
H-Index - 31
eISSN - 0974-5130
pISSN - 0377-4929
DOI - 10.4103/ijpm.ijpm_754_18
Subject(s) - adenocarcinoma , oncogene , receptor tyrosine kinase , cancer research , biology , tyrosine kinase , immunohistochemistry , signal transduction , lung cancer , cancer , pathology , medicine , cell cycle , immunology , microbiology and biotechnology
C-ros oncogene 1, receptor tyrosine kinase (ROS 1) proto-oncogene 1, receptor tyrosine kinase (ROS-1) fusions are potent oncogenic drivers and these re-arrangements promote signal transduction programs leading to uninhibited cell survival and proliferation identified in 1-2% of cases of nonsmall-cell lung cancer. Mesenchymal epithelial transition factor (MET) receptor tyrosine kinase and its ligand are predominantly involved in epithelial mesenchymal transition and tissue regeneration. The MET amplification and overexpression is oncogenic in 3-7% cases. The objectives of this study were to identify the frequency of ROS-1 and c-MET protein expression in adenocarcinoma lung and to correlate it with the clinicopathological parameters and to analyze the histomorphology of cases that harbor the characteristic mutations (c-MET and ROS-1).